longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Quince Therapeutics

QNCX

29.5502.04% ( +0.590 )
Closed: Sep 11, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • The Unbundled Margins: Why Niche Markets Defy Aggregation Theory

    Global Report·Sep 9 at 10:12 AM
    QNCX+2.04%MVST-4.14%
  • Quince Therapeutics flags Nasdaq noncompliance after stockholders’ equity falls to ($35.32 million)

    PUBT·Sep 4 at 12:30 PM
    QNCX+2.04%
  • Quince Therapeutics to Participate in September 2026 Investor Conferences

    Unusual Whales·Sep 3 at 12:02 PM
    QNCX+2.04%
  • Quince Therapeutics to present at Cantor Global Healthcare Conference

    PUBT·Sep 3 at 12:02 PM
    QNCX+2.04%
  • US Mid-Caps Surge as Micro-Caps Face Compliance Hurdles in 2026

    Global Report·Sep 2 at 10:12 AM
    - US mid-cap and micro-cap companies displayed mixed financial performances in 2026, with firms like The Hanover Insurance Group and Timken reporting strong quarterly earnings and dividend hikes, while others faced severe operational and compliance pressures. - Strategic transactions and portfolio adjustments drove growth for several entities, including Array Technologies acquiring Affordable Wire Management and Forward Air achieving record quarterly revenue despite operational losses. - Meanwhile, micro-caps such as Integrated Media Technology and Infobird struggled with Nasdaq delisting warnings and low stock prices, while firms like Quince Therapeutics restructured debt.
    HQ-1.49%IMTE-0.28%
  • Quince Therapeutics President Charles Ryan to exit Sept. 8

    PUBT·Aug 27 at 08:32 PM
    QNCX+2.04%
  • Quince Therapeutics announces special shareholder meeting

    PUBT·Aug 25 at 12:32 PM
    QNCX+2.04%
  • Quince Therapeutics raises USD 115 million in private placement of Series C preferred shares

    PUBT·Aug 17 at 10:27 AM
    QNCX+2.04%
  • QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026

    Quartr·Aug 14 at 12:24 PM
    QNCX+2.04%
  • Quince Q2 FY26 net loss widens to $75.5 million

    PUBT·Aug 14 at 12:00 PM
    QNCX+2.04%
  • Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

    Unusual Whales·Aug 14 at 12:02 PM
    QNCX+2.04%